5F射频消融导管在经皮肾动脉交感神经消融术治疗顽固性高血压患者中的安全性和有效性

徐佑龙; 金惠根; 郜俊清; 严鹏勇; 汪志华; 杨伟; 汪蔚青; 张文全; 孙剑光; 桑震池; 胡凯; 胡文瑛; 张颖; 钱俊峰; 蔡振东; 李玲燕; 方平; 王明喻; 孟莉; 陈欣; 刘宗军

doi:10.13201/j.issn.1001-1439.2014.07.016

5F射频消融导管在经皮肾动脉交感神经消融术治疗顽固性高血压患者中的安全性和有效性

- 上海中医药大学附属普陀医院心内科(上海, 200062)
基金项目:
上海市医学重点专科建设项目 (No:ZK2012B05)

详细信息

通讯作者: 刘宗军,E-mail:lzj72@126.com

中图分类号: R544.1

收稿日期: 2013-07-18

Safety and effects of catheter-based renal sympathetic denervation by 5F radiofrequency ablation catheter used in patients with resistant hypertension

- Department of Cardiology, The Putuo Affiliated Hospital of Shanghai university of TCM, Shanghai, 200062, China

More Information

Corresponding author: LIU Zongjun, E-mail: lzj72@126.com

Received Date: 18 July 2013

摘要

摘要: 目的:探索并应用5F射频消融导管在经皮肾动脉交感神经消融术 (catheter-based renal sympathetic denervation, RDN) 治疗顽固性高血压患者中的安全性和有效性。方法:本次研究共入选了10例顽固性高血压患者, 平均入院血压184/95mmHg (1mmHg=0.133kPa);平均服用药物4种, 含有1种利尿剂, 已连续服用2星期以上。完善相关检查后行RDN术, 术后复查肾动脉造影。所有患者RDN术后继续监测血压, 并于术后1周、1个月、2个月、3个月随访血压、肾功能, 并于术后3个月复查肾动脉CT血管造影。结果:10名患者均成功完成RDN术。术后复查肾动脉, 所有肾动脉均未见狭窄。在RDN术后3个月, 所有患者血压平均下降 (43±14)/(9±4) mmHg, 收缩压术前与术后3个月为 (184±14) mmHg与 (141±8) mmHg, 平均下降23.4%, P＜0.001;舒张压术前与术后3个月为 (95±7) mmHg与 (86±5) mmHg, 平均下降9.5%, P＜0.001。结论:5F射频消融导管可安全有效地在临床RDN手术中使用。
- 经皮肾动脉交感神经消融术 /
- 5F射频消融导管 /
- 顽固性高血压
Abstract: Objective: To study the safety and effects of catheter-based renal sympathetic denervation (RDN) by 5F radiofrequency ablation catheter on patients with resistant hypertension.Method: RDN were performe on 10 patients with resistant hypertension.Standardized BP measurements were obtained in all patients on dialysis free days at baseline and follow up (1week, 1 month, 2 months, 3 months).The renal artery CTA were obtained 3months after RND.Result: Average office BP was 184/95mmHg, despite the use of 4antihypertensive drugs.All10 patients underwent RDN successfully.Compared with baseline, office systolic and diastolic BP reduced 3month after RDN, from (184±14) to (141±8) mmHg, P＜0.001andfrom (95±7) to (86±5) mmHg, P＜0.001.Conclusion: The 5F radiofrequency ablation catheter can be safety and effectively used in RDN in patients with resistant hypertension.
- catheter-based renal sympathetic denervation /
- 5F radiofrequency ablation catheter /
- resistant hypertension

HTML全文

参考文献(7)

[1]	LLOYD-JONES D, ADAMS R J, BROWN T M, et al.Heart disease and stroke statistics:2010update:a report from the American Heart Association[J].Circulation, 2010, 121:e46-e215.
[2]	WOLF-MAIER K, COOPER R S, KRAMER H, et al.Hypertension treatment and control in five European countries, Canada, and the United States[J].Hypertension, 2004, 43:10-17.
[3]	CALHOUN D A, JONES D, TEXTOR S, et al.Resistant hypertension:diagnosis, evaluation, and treatment.A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J].Hypertension, 2008, 51:1403-1419.
[4]	ESLER M D, KRUM H, SOBOTKA P A, et al, for the Symplicity HTN-2 Investigators.Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial[J].Lancet, 2010, 376:1903-1909.
[5]	KEARNEY P M, WHELTON M, REYNOLDS K, et al.Global burden of hypertension:analysis of worldwide data[J].Lancet, 2005, 365:217-223.
[6]	LOWEL H, MEISINGER C, HEIER M, et al.Epidemiology of hypertension in Germany.Selected results of population-representative cross-sectional studies[J].Dtsch Med Wochenschr, 2006, 131:2586-2591.
[7]	ESLER M D, KRUM H, SCHLAICH M, et al.Renal Sympathetic denervation for treatment of drug-resistant hypertension:one-year results from the symplicity HTN-2randomized, controlled trial[J].Circulation, 2012, 126:2976-2982.